B cell M-CLL clones retain selection against replacement mutations in their immunoglobulin gene framework regions.
B lymphocytes
antibody
chronic lymphocytic leukemia (CLL)
high-throughput sequencing (HTS)
immunoglobulin (Ig)
lineage trees
machine learning (ML)
somatic hypermutation (SHM)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
12
2022
accepted:
03
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, accounting for 30-40% of all adult leukemias. The dynamics of B-lymphocyte CLL clones with mutated immunoglobulin heavy chain variable region (IgHV) genes in their tumor (M-CLL) can be studied using mutational lineage trees. Here, we used lineage tree-based analyses of somatic hypermutation (SHM) and selection in M-CLL clones, comparing the dominant (presumably malignant) clones of 15 CLL patients to their non-dominant (presumably normal) B cell clones, and to those of healthy control repertoires. This type of analysis, which was never previously published in CLL, yielded the following novel insights. CLL dominant clones undergo - or retain - more replacement mutations that alter amino acid properties such as charge or hydropathy. Although, as expected, CLL dominant clones undergo weaker selection for replacement mutations in the complementarity determining regions (CDRs) and against replacement mutations in the framework regions (FWRs) than non-dominant clones in the same patients or normal B cell clones in healthy controls, they surprisingly retain some of the latter selection in their FWRs. Finally, using machine learning, we show that even the non-dominant clones in CLL patients differ from healthy control clones in various features, most notably their expression of higher fractions of transition mutations. Overall, CLL seems to be characterized by significant loosening - but not a complete loss - of the selection forces operating on B cell clones, and possibly also by changes in SHM mechanisms.
Identifiants
pubmed: 37007112
doi: 10.3389/fonc.2023.1115361
pmc: PMC10060519
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1115361Informations de copyright
Copyright © 2023 Neuman, Arrouasse, Benjamini, Mehr and Kedmi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunology. 2005 Oct;116(2):172-83
pubmed: 16162266
Front Immunol. 2020 Aug 06;11:1734
pubmed: 32849618
Front Oncol. 2021 Nov 03;11:771454
pubmed: 34804974
Immunology. 2020 Jul;160(3):233-247
pubmed: 32031242
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6
pubmed: 18723673
Bioinformatics. 2014 Jul 1;30(13):1930-2
pubmed: 24618469
J Clin Exp Hematop. 2020 Dec 15;60(4):146-158
pubmed: 33148933
Leukemia. 2017 Apr;31(4):837-845
pubmed: 27795555
Bioinformatics. 2015 Oct 15;31(20):3356-8
pubmed: 26069265
Blood. 2004 May 1;103(9):3490-5
pubmed: 14695232
Curr Oncol Rep. 2022 Feb;24(2):209-213
pubmed: 35061199
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
BMC Bioinformatics. 2017 Sep 7;18(1):401
pubmed: 28882107
Nucleic Acids Res. 2012 Sep 1;40(17):e134
pubmed: 22641856
Front Immunol. 2014 Jun 03;5:264
pubmed: 24917868
PLoS One. 2015 Sep 01;10(9):e0134833
pubmed: 26325507
J Theor Biol. 2008 Nov 21;255(2):210-22
pubmed: 18786548
Front Oncol. 2020 Jan 31;10:67
pubmed: 32083012
Mol Biol Evol. 2016 May;33(5):1147-57
pubmed: 26802217
Nat Biotechnol. 2017 Sep;35(9):879-884
pubmed: 28829438
Am J Hematol. 2016 Mar;91(3):330-40
pubmed: 26690614
Blood. 2012 Aug 9;120(6):1175-84
pubmed: 22715122
Int Immunol. 2008 May;20(5):683-94
pubmed: 18397909
J Natl Compr Canc Netw. 2015 Mar;13(3):326-62
pubmed: 25736010
J Mol Biol. 1982 May 5;157(1):105-32
pubmed: 7108955
Int J Mol Sci. 2020 Mar 06;21(5):
pubmed: 32155826
Annu Rev Immunol. 2008;26:481-511
pubmed: 18304001
Cell. 2018 Jun 14;173(7):1783-1795.e14
pubmed: 29731169
Blood. 2013 Feb 28;121(9):1604-11
pubmed: 23297126
Front Immunol. 2022 Oct 26;13:822834
pubmed: 36389731
Immunity. 2021 Aug 10;54(8):1652-1664
pubmed: 34380063
EMBO J. 1985 Feb;4(2):345-50
pubmed: 3926481
Microbiol Spectr. 2014 Apr;2(2):
pubmed: 26105823
J Immunol Methods. 2008 Sep 30;338(1-2):67-74
pubmed: 18706908
BMC Bioinformatics. 2019 May 28;20(1):267
pubmed: 31138102
Int Immunol. 2010 Nov;22(11):875-87
pubmed: 21059768
Hematology Am Soc Hematol Educ Program. 2011;2011:96-103
pubmed: 22160019
J Immunol. 2011 May 15;186(10):6044-55
pubmed: 21498665
J Immunol. 2017 Oct 15;199(8):2985-2997
pubmed: 28924003
Front Immunol. 2021 Jul 22;12:680687
pubmed: 34367141
Front Immunol. 2021 Mar 10;12:627813
pubmed: 33790900
Immunology. 1998 Nov;95(3):339-45
pubmed: 9824495
J Theor Biol. 1966 Nov;12(2):157-95
pubmed: 4291386
Front Immunol. 2022 Aug 29;13:957170
pubmed: 36105806
Exp Hematol. 2021 Jan;93:14-24
pubmed: 32976948
J Immunol. 1999 Apr 1;162(7):3950-6
pubmed: 10201914
Front Oncol. 2022 Nov 10;12:1029995
pubmed: 36439408
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D256-61
pubmed: 15608191
Front Immunol. 2021 Mar 15;12:626793
pubmed: 33790897
Blood. 2011 Oct 20;118(16):4313-20
pubmed: 21816833
Mediterr J Hematol Infect Dis. 2012;4(1):e2012067
pubmed: 23170196
J Clin Immunol. 2007 Jan;27(1):69-87
pubmed: 17192818
Front Immunol. 2018 Aug 10;9:1784
pubmed: 30147686
J Mol Recognit. 2004 Jan-Feb;17(1):17-32
pubmed: 14872534
Cancer Cell. 2020 May 11;37(5):655-673.e11
pubmed: 32396861
Elife. 2021 Oct 18;10:
pubmed: 34661527
Int J Lab Hematol. 2022 Oct;44(5):e239-e242
pubmed: 35706357
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713
Front Immunol. 2018 Feb 21;9:224
pubmed: 29515569